

## AMENDMENT

### In the Claims:

Please replace claims 15, 17-21 and 23 with the following claims 15, 17-21 and 23.

B' <sup>sub C'</sup> 15. (Amended) A liposomal-based preparation useful as an infant formula, comprising a natural bilayer-forming lipid component and an active ingredient component, wherein the lipid component consists of a phospholipid concentration of between 0.2% to 2.0% (w/w) of the total liposome composition, and wherein the active ingredient component comprises one or more components selected from the group consisting of micronutrients, proteins, immunoglobulins, vitamins and minerals.

B2 <sup>cont C'</sup> 17. (Amended) The liposome preparation of claim 15, wherein the phospholipid concentration is between 1% to 2% of the total liposome composition.

18. (Amended) The liposome preparation of claim 15, wherein the lipid component is selected from the group consisting of glycerolphospholipids, sphingophospholipids, and mixtures thereof.

19. (Amended) The liposome preparation of claim 18, wherein the lipid component is selected from the group consisting of glyceroglycolipids, sphinogoglycolipids, and mixtures thereof.

20. (Amended) The liposome preparation of claim 19, further comprising a stabilizer, wherein the stabilizer is selected from the group consisting of cholesterol, stigmasterol, carrageenan, and mixtures thereof.

21. (Amended) The liposome preparation of claim 20, wherein the concentration of the stabilizer comprises 0.05% to 30% w/w of the liposome preparation.

B3 <sup>cont C'</sup> 23. (Amended) The liposome preparation of claim 15, wherein the liposome preparation includes liposomes having a size range between 50nm and 100nm.